Quantum BioPharma (NASDAQ: QNTM) is issuing Contingent Value Rights to its shareholders as a special dividend, linked to the outcome of a pending $700 million+ litigation. Shareholders will receive a pro rata share of 10-50% of recovered proceeds, determined by the board later. The aim is to align shareholder interests with legal outcomes, with the CVRs being non-tradable, non-voting, and only payable in cash upon successful recovery of funds.
